PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.95%
Revenue growth above 1.5x 3088.T's 0.99%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
9.53%
Gross profit growth above 1.5x 3088.T's 1.57%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
43.67%
EBIT growth 1.25-1.5x 3088.T's 34.09%. Bruce Berkowitz would verify if strategic initiatives are driving this edge.
30.10%
Operating income growth above 1.5x 3088.T's 8.02%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
42.72%
Net income growth at 50-75% of 3088.T's 59.50%. Martin Whitman would question fundamental disadvantages in expenses or demand.
42.72%
EPS growth at 50-75% of 3088.T's 59.50%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
42.72%
Diluted EPS growth at 50-75% of 3088.T's 59.40%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.78%
10Y revenue/share CAGR at 50-75% of 3088.T's 38.47%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
-7.65%
Negative 5Y CAGR while 3088.T stands at 26.93%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
35.01%
3Y revenue/share CAGR above 1.5x 3088.T's 13.36%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
70.39%
Net income/share CAGR at 50-75% of 3088.T's 135.48%. Martin Whitman might question if the firm’s product or cost base lags behind.
2.81%
Below 50% of 3088.T's 141.46%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
47.84%
3Y net income/share CAGR 50-75% of 3088.T's 70.14%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
28.23%
Below 50% of 3088.T's 63.58%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
68.77%
3Y equity/share CAGR above 1.5x 3088.T's 25.62%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-99.16%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-2.48%
Inventory is declining while 3088.T stands at 3.83%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.44%
Positive asset growth while 3088.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
5.18%
BV/share growth above 1.5x 3088.T's 1.42%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-25.72%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
101.71%
SG&A growth well above 3088.T's 25.02%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.